Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Vaccine sales drive growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck

3Q Revenues: $10.5 billion (+5%)

3Q Earnings: $2.2 billion (+19%)

YTD Revenues: $29.7 billion (+1%)

YTD Earnings: $4.5 billion (+30%)

Comments: Pharmaceutical sales were up 6% in the quarter to $9.4 billion, reflecting higher vaccines sales, oncology, cardiovascular franchise sales and hospital acute care. Sales of GARDASIL 9 and GARDASIL were up 38% to $860 million and PROQUAD / M-M-R II sales were up 27% to $496 million, driven by the timing of sales activity in the third quarter of 2015 related to the Pediatric Vaccine Stockpile of the U.S. CDC. Zepatier sales were $326 million in the quarter. Growth in oncology was driven by KEYTRUDA, with sales were up 124% to $356 million as new indications were launched globally. Higher sales in the cardiovascular portfolio were driven by ZETIA up 6% to $671 million, helping to offset by lower sale sales of Vytorin, down 10% to $273 million. Remicade sales were down 30% to $311 million. Isentress sales were $372 million, down 1%. Results includes a $117 million gain related to the settlement of certain patent litigation. Other (income) expense in the quarter and first nine months of 2015 includes a $250 million gain on the sale of certain migraine clinical development programs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters